This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on more ...

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...

Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity ...

NEW YORK] WeightWatchers, known for its diet programmes once endorsed by celebrities including Oprah Winfrey, has filed for ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Despite the $1,000-per-dose price tag, GLP-1s may offer long-term ROI by lowering chronic disease rates GLP-1 weight loss ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

GLP-1 drugs such as Ozempic and Wegovy have been generating a buzz. Initially developed to treat type 2 diabetes, these drugs ...